CAS 1334302-63-4

2-(3-(4-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-1-(1-(3-fluoro-2-(trifluoromethyl)isonicotinoyl)piperidin-4-yl)azetidin-3-yl)acetonitrile adipate

CAS : 1334302-63-4

2-(3-(4-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-1-(1-(3-fluoro-2-(trifluoromethyl)isonicotinoyl)piperidin-4-yl)azetidin-3-yl)acetonitrile adipate

Degré de pureté : 98%

Masse moléculaire : 699.67g/mol

Ref: 54-PC1007770

Itacitinib adipate

CAS : 1334302-63-4

Itacitinib adipate: oral JAK1 inhibitor, tested in phase II myelofibrosis trial.

Formule : C₃₂H₃₃F₄N₉O₅

Couleur et forme : Solid

Masse moléculaire : 699.66

Ref: TM-T11687

Itacitinib adipate

CAS : 1334302-63-4

Itacitinib adipate is a potential antineoplastic agent that inhibits the expression of genes involved in the inflammatory response. It is a bioavailable inhibitor of JAK1 and JAK2 proteins, which are signal transducers for inflammatory cytokines. Itacitinib adipate has been shown to be effective against chronic inflammatory diseases such as colitis, mediated by TNF-α, and myelofibrosis, mediated by IL-6. Clinical trials have shown that itacitinib adipate can be used to treat inflammatory skin diseases such as psoriasis.

Formule : C₃₂H₃₃F₄N₉O₅

Degré de pureté : Min. 95%

Masse moléculaire : 699.7 g/mol

Ref: 3D-JDC30263